
    
      The investigators will first identify acute respiratory distress syndrome (ARDS) patients
      receiving ECMO support in ICU at National Taiwan University Hospital, and then collect blood,
      urine and bronchioalveolar lavage fluid (BALF) samples at different time points: before
      setting up ECMO, 2, 6, 12, 24, 72 hours,5 and 14 days after ECMO installment, time to wean
      ECMO and the day removing ECMO and leaving ICU. From the samples, the free radicals,
      cytokines (IL-1, IL-6, IL-8, IL-18,tumor necrosis factor-α, transforming growth factor-β),
      and inflammasome- related markers, immune cell responses and other biochemical markers would
      be measured. The novel biomarkers to predict the outcome of the patient will be identified.
    
  